Success Metrics

Clinical Success Rate
28.6%

Based on 2 completed trials

Completion Rate
29%(2/7)
Active Trials
0(0%)
Results Posted
300%(6 trials)
Terminated
5(71%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_1
4
57%

Phase Distribution

4

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

28.6%

2 of 7 finished

Non-Completion Rate

71.4%

5 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(2)
Terminated(5)

Detailed Status

Terminated5
Completed2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
28.6%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 23 (42.9%)

Trials by Status

terminated571%
completed229%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_2

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04987307
terminatedphase_2

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05672199
terminatedphase_2

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

NCT04680637
completedphase_1

Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants

NCT04987333
terminatedphase_1

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

NCT03422627
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04987307Phase 2

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Terminated
NCT05672199Phase 2

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Terminated
NCT04680637Phase 2

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Terminated
NCT04987333Phase 1

Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants

Completed
NCT03422627Phase 1

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Terminated
NCT03451422Phase 1

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

Completed
NCT03410056Phase 1

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7